Efficacy of intravitreal bevacizumab after unresponsive treatment with intravitreal ranibizumab
- 1 April 2011
- journal article
- Published by Elsevier BV in Canadian Journal of Ophthalmology
- Vol. 46 (2), 182-185
- https://doi.org/10.3129/i10-095
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Comparison of Bevacizumab, Ranibizumab, and Pegaptanib In Vitro: Efficiency and Possible Additional PathwaysInvestigative Ophthalmology & Visual Science, 2008
- An Optical Coherence Tomography-Guided, Variable Dosing Regimen with Intravitreal Ranibizumab (Lucentis) for Neovascular Age-related Macular DegenerationAmerican Journal of Ophthalmology, 2007
- Intravitreal VEGF-inhibitors: is Avastin® a generic substitute for Lucentis®?Acta Ophthalmologica Scandinavica, 2007
- Ranibizumab versus Verteporfin for Neovascular Age-Related Macular DegenerationThe New England Journal of Medicine, 2006
- Ranibizumab for Neovascular Age-Related Macular DegenerationThe New England Journal of Medicine, 2006
- The Price of Sight — Ranibizumab, Bevacizumab, and the Treatment of Macular DegenerationThe New England Journal of Medicine, 2006
- Intravitreal Bevacizumab for the Management of Choroidal Neovascularization in Age-related Macular DegenerationAmerican Journal of Ophthalmology, 2006
- Intravitreal Bevacizumab (Avastin) for Neovascular Age-Related Macular DegenerationOphthalmology, 2006